Tenofovir disoproxil fumarate has a substantial efficacy against multidrug-resistant strains of hepatitis B virus
Background & Aims To evaluate the efficacy of tenofovir in chronic hepatitis B (CHB) patients with adefovir resistance (ADF‐R) and suboptimal response to adefovir (ADF‐S). Methods Nucleos(t)ide analogue (NA)‐naïve patients and patients with previous adefovir failure receiving tenofovir therapy f...
Gespeichert in:
| Veröffentlicht in: | Liver international 2015-10, Vol.35 (10), p.2265-2274 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 2274 |
|---|---|
| container_issue | 10 |
| container_start_page | 2265 |
| container_title | Liver international |
| container_volume | 35 |
| creator | Baran, Bulent Soyer, Ozlem Mutluay Ormeci, Asli Cifcibasi Gokturk, Suut Evirgen, Sami Akyuz, Filiz Karaca, Cetin Demir, Kadir Besisik, Fatih Onel, Derya Gulluoglu, Mine Badur, Selim Kaymakoglu, Sabahattin |
| description | Background & Aims
To evaluate the efficacy of tenofovir in chronic hepatitis B (CHB) patients with adefovir resistance (ADF‐R) and suboptimal response to adefovir (ADF‐S).
Methods
Nucleos(t)ide analogue (NA)‐naïve patients and patients with previous adefovir failure receiving tenofovir therapy for at least 6 months were included in the study. Biochemical and virological tests were obtained at baseline and 3‐month intervals in the first year and every 6 months thereafter. The primary outcome measure was complete virological response (CVR) (HBVDNA |
| doi_str_mv | 10.1111/liv.12831 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1717484710</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1717484710</sourcerecordid><originalsourceid>FETCH-LOGICAL-c4331-c0098847c54f09b240b08caf87d6dd64b087c051049da940640163de00af94ed3</originalsourceid><addsrcrecordid>eNp1kEtPGzEURi3Uikdg0T9QedkuhlyPPeOZZYsojRS1IF4SG8vxA9xOMsHXE8i_ryGQXb2xr3zud-1DyCcGxyyvcRdWx6xsONsh-0zIpuAlZx-255LvkQPEPwCsbSu2S_bKqgFopdgnj1du0ft-FSK1Aftl7J9DR_0w11EnRx80Uk1xmGHSixR0R533wWizpvpehwUmOh-6FGwc7ovoMLxyFFN8uaS9pw9uqVNIAel3mqcMeEg-et2hO3rbR-T6x-nVyc9i-vtscvJtWhjBOStMfmDTCGkq4aGdlQJm0BjtG2lra2uRK2mgYiBaq1sBtQBWc-sAtG-Fs3xEvmxy858eB4dJzQMa13V64foBFZNMijyAQUa_blATe8TovFrGkA2sFQP1Ylhlw-rVcGY_v8UOs7mzW_JdaQbGG-ApdG79_yQ1ndy8RxabjmzPPW87dPyrasllpW5_nanL84tbuCsv1A3_B-ASlkY</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1717484710</pqid></control><display><type>article</type><title>Tenofovir disoproxil fumarate has a substantial efficacy against multidrug-resistant strains of hepatitis B virus</title><source>MEDLINE</source><source>Access via Wiley Online Library</source><creator>Baran, Bulent ; Soyer, Ozlem Mutluay ; Ormeci, Asli Cifcibasi ; Gokturk, Suut ; Evirgen, Sami ; Akyuz, Filiz ; Karaca, Cetin ; Demir, Kadir ; Besisik, Fatih ; Onel, Derya ; Gulluoglu, Mine ; Badur, Selim ; Kaymakoglu, Sabahattin</creator><creatorcontrib>Baran, Bulent ; Soyer, Ozlem Mutluay ; Ormeci, Asli Cifcibasi ; Gokturk, Suut ; Evirgen, Sami ; Akyuz, Filiz ; Karaca, Cetin ; Demir, Kadir ; Besisik, Fatih ; Onel, Derya ; Gulluoglu, Mine ; Badur, Selim ; Kaymakoglu, Sabahattin</creatorcontrib><description>Background & Aims
To evaluate the efficacy of tenofovir in chronic hepatitis B (CHB) patients with adefovir resistance (ADF‐R) and suboptimal response to adefovir (ADF‐S).
Methods
Nucleos(t)ide analogue (NA)‐naïve patients and patients with previous adefovir failure receiving tenofovir therapy for at least 6 months were included in the study. Biochemical and virological tests were obtained at baseline and 3‐month intervals in the first year and every 6 months thereafter. The primary outcome measure was complete virological response (CVR) (HBVDNA < 20 IU/ml). CVR rates were calculated by Kaplan–Meier analysis, and a multivariate Cox proportional hazard model was generated to find out factors independently associated with CVR.
Results
A total of 165 patients (118 men, mean age 42 ± 12, 64 HBeAg+) were included in the study. There were 105 patients in NA‐naïve, 32 patients in ADF‐S and 28 patients in ADF‐R groups. All patients in the ADF‐R group had multidrug resistance patterns. Mean duration of tenofovir treatment was 29 ± 14 months. CVR rates in NA‐naïve, ADF‐S and ADF‐R groups were 65% vs. 75% vs. 58% at 12th month, 77% vs. 87% vs. 79% at 24th month and 83% vs. 94% vs. 79% at 36th month respectively. According to multivariate Cox regression model, HBeAg positivity (HR = 0.56, 95%CI 0.36–0.86, P = 0.008), high baseline HBVDNA level (HR = 0.64, 95%CI 0.55–0.74, P < 0.001) and ADF‐R (HR = 0.47, 95%CI 0.28–0.81, P = 0.006) were independent predictors for CVR. Seven patients encountered mild renal dysfunction and were managed by dose adjustments.
Conclusion
CVR rates during the follow‐up show that tenofovir has a decreased, yet still potent in vivo efficacy against multidrug‐resistant strains of HBV.</description><identifier>ISSN: 1478-3223</identifier><identifier>EISSN: 1478-3231</identifier><identifier>DOI: 10.1111/liv.12831</identifier><identifier>PMID: 25800974</identifier><language>eng</language><publisher>United States: Blackwell Publishing Ltd</publisher><subject>adefovir failure ; Adolescent ; Adult ; Aged ; Alanine Transaminase ; Antiviral Agents - administration & dosage ; chronic hepatitis B ; DNA, Viral ; Drug Resistance, Viral ; Female ; genotypic resistance ; Hepatitis B e Antigens - blood ; Hepatitis B virus - drug effects ; Hepatitis B virus - genetics ; Hepatitis B, Chronic - drug therapy ; Humans ; Kaplan-Meier Estimate ; Male ; Middle Aged ; Multivariate Analysis ; Proportional Hazards Models ; Tenofovir - administration & dosage ; tenofovir disoproxil fumarate ; Treatment Outcome ; Viral Load ; Young Adult</subject><ispartof>Liver international, 2015-10, Vol.35 (10), p.2265-2274</ispartof><rights>2015 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd</rights><rights>2015 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c4331-c0098847c54f09b240b08caf87d6dd64b087c051049da940640163de00af94ed3</citedby><cites>FETCH-LOGICAL-c4331-c0098847c54f09b240b08caf87d6dd64b087c051049da940640163de00af94ed3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1111%2Fliv.12831$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1111%2Fliv.12831$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>314,780,784,1417,27924,27925,45574,45575</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/25800974$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Baran, Bulent</creatorcontrib><creatorcontrib>Soyer, Ozlem Mutluay</creatorcontrib><creatorcontrib>Ormeci, Asli Cifcibasi</creatorcontrib><creatorcontrib>Gokturk, Suut</creatorcontrib><creatorcontrib>Evirgen, Sami</creatorcontrib><creatorcontrib>Akyuz, Filiz</creatorcontrib><creatorcontrib>Karaca, Cetin</creatorcontrib><creatorcontrib>Demir, Kadir</creatorcontrib><creatorcontrib>Besisik, Fatih</creatorcontrib><creatorcontrib>Onel, Derya</creatorcontrib><creatorcontrib>Gulluoglu, Mine</creatorcontrib><creatorcontrib>Badur, Selim</creatorcontrib><creatorcontrib>Kaymakoglu, Sabahattin</creatorcontrib><title>Tenofovir disoproxil fumarate has a substantial efficacy against multidrug-resistant strains of hepatitis B virus</title><title>Liver international</title><addtitle>Liver Int</addtitle><description>Background & Aims
To evaluate the efficacy of tenofovir in chronic hepatitis B (CHB) patients with adefovir resistance (ADF‐R) and suboptimal response to adefovir (ADF‐S).
Methods
Nucleos(t)ide analogue (NA)‐naïve patients and patients with previous adefovir failure receiving tenofovir therapy for at least 6 months were included in the study. Biochemical and virological tests were obtained at baseline and 3‐month intervals in the first year and every 6 months thereafter. The primary outcome measure was complete virological response (CVR) (HBVDNA < 20 IU/ml). CVR rates were calculated by Kaplan–Meier analysis, and a multivariate Cox proportional hazard model was generated to find out factors independently associated with CVR.
Results
A total of 165 patients (118 men, mean age 42 ± 12, 64 HBeAg+) were included in the study. There were 105 patients in NA‐naïve, 32 patients in ADF‐S and 28 patients in ADF‐R groups. All patients in the ADF‐R group had multidrug resistance patterns. Mean duration of tenofovir treatment was 29 ± 14 months. CVR rates in NA‐naïve, ADF‐S and ADF‐R groups were 65% vs. 75% vs. 58% at 12th month, 77% vs. 87% vs. 79% at 24th month and 83% vs. 94% vs. 79% at 36th month respectively. According to multivariate Cox regression model, HBeAg positivity (HR = 0.56, 95%CI 0.36–0.86, P = 0.008), high baseline HBVDNA level (HR = 0.64, 95%CI 0.55–0.74, P < 0.001) and ADF‐R (HR = 0.47, 95%CI 0.28–0.81, P = 0.006) were independent predictors for CVR. Seven patients encountered mild renal dysfunction and were managed by dose adjustments.
Conclusion
CVR rates during the follow‐up show that tenofovir has a decreased, yet still potent in vivo efficacy against multidrug‐resistant strains of HBV.</description><subject>adefovir failure</subject><subject>Adolescent</subject><subject>Adult</subject><subject>Aged</subject><subject>Alanine Transaminase</subject><subject>Antiviral Agents - administration & dosage</subject><subject>chronic hepatitis B</subject><subject>DNA, Viral</subject><subject>Drug Resistance, Viral</subject><subject>Female</subject><subject>genotypic resistance</subject><subject>Hepatitis B e Antigens - blood</subject><subject>Hepatitis B virus - drug effects</subject><subject>Hepatitis B virus - genetics</subject><subject>Hepatitis B, Chronic - drug therapy</subject><subject>Humans</subject><subject>Kaplan-Meier Estimate</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Multivariate Analysis</subject><subject>Proportional Hazards Models</subject><subject>Tenofovir - administration & dosage</subject><subject>tenofovir disoproxil fumarate</subject><subject>Treatment Outcome</subject><subject>Viral Load</subject><subject>Young Adult</subject><issn>1478-3223</issn><issn>1478-3231</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2015</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp1kEtPGzEURi3Uikdg0T9QedkuhlyPPeOZZYsojRS1IF4SG8vxA9xOMsHXE8i_ryGQXb2xr3zud-1DyCcGxyyvcRdWx6xsONsh-0zIpuAlZx-255LvkQPEPwCsbSu2S_bKqgFopdgnj1du0ft-FSK1Aftl7J9DR_0w11EnRx80Uk1xmGHSixR0R533wWizpvpehwUmOh-6FGwc7ovoMLxyFFN8uaS9pw9uqVNIAel3mqcMeEg-et2hO3rbR-T6x-nVyc9i-vtscvJtWhjBOStMfmDTCGkq4aGdlQJm0BjtG2lra2uRK2mgYiBaq1sBtQBWc-sAtG-Fs3xEvmxy858eB4dJzQMa13V64foBFZNMijyAQUa_blATe8TovFrGkA2sFQP1Ylhlw-rVcGY_v8UOs7mzW_JdaQbGG-ApdG79_yQ1ndy8RxabjmzPPW87dPyrasllpW5_nanL84tbuCsv1A3_B-ASlkY</recordid><startdate>201510</startdate><enddate>201510</enddate><creator>Baran, Bulent</creator><creator>Soyer, Ozlem Mutluay</creator><creator>Ormeci, Asli Cifcibasi</creator><creator>Gokturk, Suut</creator><creator>Evirgen, Sami</creator><creator>Akyuz, Filiz</creator><creator>Karaca, Cetin</creator><creator>Demir, Kadir</creator><creator>Besisik, Fatih</creator><creator>Onel, Derya</creator><creator>Gulluoglu, Mine</creator><creator>Badur, Selim</creator><creator>Kaymakoglu, Sabahattin</creator><general>Blackwell Publishing Ltd</general><scope>BSCLL</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>201510</creationdate><title>Tenofovir disoproxil fumarate has a substantial efficacy against multidrug-resistant strains of hepatitis B virus</title><author>Baran, Bulent ; Soyer, Ozlem Mutluay ; Ormeci, Asli Cifcibasi ; Gokturk, Suut ; Evirgen, Sami ; Akyuz, Filiz ; Karaca, Cetin ; Demir, Kadir ; Besisik, Fatih ; Onel, Derya ; Gulluoglu, Mine ; Badur, Selim ; Kaymakoglu, Sabahattin</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c4331-c0098847c54f09b240b08caf87d6dd64b087c051049da940640163de00af94ed3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2015</creationdate><topic>adefovir failure</topic><topic>Adolescent</topic><topic>Adult</topic><topic>Aged</topic><topic>Alanine Transaminase</topic><topic>Antiviral Agents - administration & dosage</topic><topic>chronic hepatitis B</topic><topic>DNA, Viral</topic><topic>Drug Resistance, Viral</topic><topic>Female</topic><topic>genotypic resistance</topic><topic>Hepatitis B e Antigens - blood</topic><topic>Hepatitis B virus - drug effects</topic><topic>Hepatitis B virus - genetics</topic><topic>Hepatitis B, Chronic - drug therapy</topic><topic>Humans</topic><topic>Kaplan-Meier Estimate</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Multivariate Analysis</topic><topic>Proportional Hazards Models</topic><topic>Tenofovir - administration & dosage</topic><topic>tenofovir disoproxil fumarate</topic><topic>Treatment Outcome</topic><topic>Viral Load</topic><topic>Young Adult</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Baran, Bulent</creatorcontrib><creatorcontrib>Soyer, Ozlem Mutluay</creatorcontrib><creatorcontrib>Ormeci, Asli Cifcibasi</creatorcontrib><creatorcontrib>Gokturk, Suut</creatorcontrib><creatorcontrib>Evirgen, Sami</creatorcontrib><creatorcontrib>Akyuz, Filiz</creatorcontrib><creatorcontrib>Karaca, Cetin</creatorcontrib><creatorcontrib>Demir, Kadir</creatorcontrib><creatorcontrib>Besisik, Fatih</creatorcontrib><creatorcontrib>Onel, Derya</creatorcontrib><creatorcontrib>Gulluoglu, Mine</creatorcontrib><creatorcontrib>Badur, Selim</creatorcontrib><creatorcontrib>Kaymakoglu, Sabahattin</creatorcontrib><collection>Istex</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Liver international</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Baran, Bulent</au><au>Soyer, Ozlem Mutluay</au><au>Ormeci, Asli Cifcibasi</au><au>Gokturk, Suut</au><au>Evirgen, Sami</au><au>Akyuz, Filiz</au><au>Karaca, Cetin</au><au>Demir, Kadir</au><au>Besisik, Fatih</au><au>Onel, Derya</au><au>Gulluoglu, Mine</au><au>Badur, Selim</au><au>Kaymakoglu, Sabahattin</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Tenofovir disoproxil fumarate has a substantial efficacy against multidrug-resistant strains of hepatitis B virus</atitle><jtitle>Liver international</jtitle><addtitle>Liver Int</addtitle><date>2015-10</date><risdate>2015</risdate><volume>35</volume><issue>10</issue><spage>2265</spage><epage>2274</epage><pages>2265-2274</pages><issn>1478-3223</issn><eissn>1478-3231</eissn><abstract>Background & Aims
To evaluate the efficacy of tenofovir in chronic hepatitis B (CHB) patients with adefovir resistance (ADF‐R) and suboptimal response to adefovir (ADF‐S).
Methods
Nucleos(t)ide analogue (NA)‐naïve patients and patients with previous adefovir failure receiving tenofovir therapy for at least 6 months were included in the study. Biochemical and virological tests were obtained at baseline and 3‐month intervals in the first year and every 6 months thereafter. The primary outcome measure was complete virological response (CVR) (HBVDNA < 20 IU/ml). CVR rates were calculated by Kaplan–Meier analysis, and a multivariate Cox proportional hazard model was generated to find out factors independently associated with CVR.
Results
A total of 165 patients (118 men, mean age 42 ± 12, 64 HBeAg+) were included in the study. There were 105 patients in NA‐naïve, 32 patients in ADF‐S and 28 patients in ADF‐R groups. All patients in the ADF‐R group had multidrug resistance patterns. Mean duration of tenofovir treatment was 29 ± 14 months. CVR rates in NA‐naïve, ADF‐S and ADF‐R groups were 65% vs. 75% vs. 58% at 12th month, 77% vs. 87% vs. 79% at 24th month and 83% vs. 94% vs. 79% at 36th month respectively. According to multivariate Cox regression model, HBeAg positivity (HR = 0.56, 95%CI 0.36–0.86, P = 0.008), high baseline HBVDNA level (HR = 0.64, 95%CI 0.55–0.74, P < 0.001) and ADF‐R (HR = 0.47, 95%CI 0.28–0.81, P = 0.006) were independent predictors for CVR. Seven patients encountered mild renal dysfunction and were managed by dose adjustments.
Conclusion
CVR rates during the follow‐up show that tenofovir has a decreased, yet still potent in vivo efficacy against multidrug‐resistant strains of HBV.</abstract><cop>United States</cop><pub>Blackwell Publishing Ltd</pub><pmid>25800974</pmid><doi>10.1111/liv.12831</doi><tpages>10</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1478-3223 |
| ispartof | Liver international, 2015-10, Vol.35 (10), p.2265-2274 |
| issn | 1478-3223 1478-3231 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_1717484710 |
| source | MEDLINE; Access via Wiley Online Library |
| subjects | adefovir failure Adolescent Adult Aged Alanine Transaminase Antiviral Agents - administration & dosage chronic hepatitis B DNA, Viral Drug Resistance, Viral Female genotypic resistance Hepatitis B e Antigens - blood Hepatitis B virus - drug effects Hepatitis B virus - genetics Hepatitis B, Chronic - drug therapy Humans Kaplan-Meier Estimate Male Middle Aged Multivariate Analysis Proportional Hazards Models Tenofovir - administration & dosage tenofovir disoproxil fumarate Treatment Outcome Viral Load Young Adult |
| title | Tenofovir disoproxil fumarate has a substantial efficacy against multidrug-resistant strains of hepatitis B virus |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-27T23%3A25%3A50IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Tenofovir%20disoproxil%20fumarate%20has%20a%20substantial%20efficacy%20against%20multidrug-resistant%20strains%20of%20hepatitis%20B%20virus&rft.jtitle=Liver%20international&rft.au=Baran,%20Bulent&rft.date=2015-10&rft.volume=35&rft.issue=10&rft.spage=2265&rft.epage=2274&rft.pages=2265-2274&rft.issn=1478-3223&rft.eissn=1478-3231&rft_id=info:doi/10.1111/liv.12831&rft_dat=%3Cproquest_cross%3E1717484710%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1717484710&rft_id=info:pmid/25800974&rfr_iscdi=true |